(Big League Politics) – Pfizer CEO Albert Bourla recently did an interview with CNBC in which he stated that two doses of the Covid-19 inoculation gave “very limited protection if any,” before claiming that three doses with a booster offer reasonable protection against hospitalization, but still barely protect against infection.
“The two doses, they’re not enough for omicron,” Bourla said. “The third dose of the current vaccine is providing quite good protection against deaths, and decent protection against hospitalizations.”
CNBC also reported that data out of the United Kingdom demonstrated that two doses of Pfizer’s or Moderna’s shots, which is to say the full inoculation regimen, are only about 10% effective at preventing infection from omicron about 20 weeks after the second dose. In other words, the shot is virtually useless in regards to preventing infection less than half a year after receiving it.
Pfizer CEO on the vaccine that the U.S. government wants to mandate for the entire population:
“Two doses of the vaccine offers very limited protection, if any. 3 doses with a booster offer reasonable protection against hospitalization and deaths." pic.twitter.com/bflGbJWFzh
— Young Americans for Liberty (@YALiberty) January 10, 2022
“Two doses of the vaccine offers very limited protection, if any,” said Bourla during the interview. “3 doses with a booster offer reasonable protection against hospitalization and deaths.”
Bourla has claimed in the past that the Pfizer Covid-19 inoculations were 100% effective in preventing the illness.
“Excited to share that updated analysis from our Phase 3 study with BioNTech also showed that our COVID-19 vaccine was 100% effective in preventing #COVID19 cases in South Africa,” the Pfizer CEO wrote back in April. “100%!”
Excited to share that updated analysis from our Phase 3 study with BioNTech also showed that our COVID-19 vaccine was 100% effective in preventing #COVID19 cases in South Africa. 100%! https://t.co/E2ksTJSopU
— Albert Bourla (@AlbertBourla) April 1, 2021
In other recent news, Bourla has announced a 4th dose of the Pfizer Covid-19 inoculation supposedly targeted at the very mild Omicron variant, promising it will be ready by this March.
“We [are] already starting manufacturing some of these quantities at risk,” Bourla said. “The hope is that we will achieve something that will have way, way better protection particularly against infections, because the protection against the hospitalizations and the severe disease — it is reasonable right now, with the current vaccines as long as you are having let’s say the third dose.”